Trials / Recruiting
RecruitingNCT05029063
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters: a Randomized Controlled Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,828 (estimated)
- Sponsor
- Ottawa Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Detailed description
TRIM-Line is a double blind randomized controlled trial comparing rivaroxaban 10mg po daily vs placebo in patients with active cancer and indwelling CVC. This will involve 9 centers across Canada.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban 10 MG | Identical comparator drug |
Timeline
- Start date
- 2022-10-05
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2021-08-31
- Last updated
- 2025-07-09
Locations
11 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT05029063. Inclusion in this directory is not an endorsement.